×

Get the Prostate Cancer Patient Guide as a digital download or free mailed copy.

Click here.

07-13_BreakingNews_FeaturedImg745x510

UCLA, UCSF gain FDA approval for prostate cancer imaging technique

The University of California's two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a...Read More

spear_745x510

The Prostate Cancer Foundation and Robert F. Smith Announce New Effort to Address Health Disparities for African American Men

LOS ANGELES, Calif., July 21, 2020 – The Prostate Cancer Foundation (PCF) and Robert F. Smith, founder, chairman and CEO of Vista Equity Partners, announce a new effort to reduce...Read More

Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer

Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients...Read More

Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy

Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy

Rubraca is the first PARP inhibitor approved in a prostate cancer setting  Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical...Read More

07-13_BreakingNews_FeaturedImg745x510

FDA approves enzalutamide for metastatic castration-sensitive prostate cancer

December 16, 2019 – Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC).  Enzalutamide has...Read More

07-13_BreakingNews_FeaturedImg745x510

FDA Approves Enzalutamide (Xtandi) for Non-Metastatic Castration-Resistant Prostate Cancer

July 13, 2018 – Today the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC).  Non-metastatic CRPC is a clinical...Read More

Prostate Cancer Foundation’s Statement on Late-Breaking ASCO Presentation Regarding Racial Differences in Prostate Cancer and Call for Greater Diversity in Clinical Trial Participation

Prostate Cancer Foundation’s Statement on Late-Breaking ASCO Presentation Regarding Racial Differences in Prostate Cancer and Call for Greater Diversity in Clinical Trial Participation

JUNE 1, 2018  - Each year three million men in the U.S. battle prostate cancer and on average one in nine men will be diagnosed in their lifetime. However, there...Read More

BreakingNews_FeaturedImg745x510(030718).jpg

Prostate Cancer Foundation Statement on U.S. Preventive Services Task Force Updated Prostate Screening Guidelines

Yesterday, the USPSTF updated its 2012 position on prostate cancer screening recommending that clinicians should selectively offer or provide periodic prostate-specific antigen (PSA)–based screening for prostate cancer for men between...Read More

PSMA-TargetedClincalTrial_FeaturedImg745x510(sg_02)

Clinical trial finds strong promise for new treatment that targets radiation directly to prostate cancer

May 8, 2018  A study published today in Lancet Oncology reported highly promising results from a phase 2 clinical trial testing a new treatment, 177Lu-PSMA-617, which targets radiation directly to prostate...Read More

New NCCN Guidelines Incorporate PCF-Funded Research on Cancer Risk Genes

New NCCN Guidelines Incorporate PCF-Funded Research on Cancer Risk Genes

Thanks in large part to the kinds of genetic and precision medicine that the Prostate Cancer Foundation has been funding, the National Comprehensive Cancer Network (NCCN) has issued updated prostate...Read More